Want to see SBFM full AI Analyst Report?
Top Page
Sunshine Biopharma
(NASDAQ:SBFM)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.16
▼(-86.05% Downside)
Action:Upgraded
Date:10/23/26
The score is driven primarily by weak financial performance (declining revenue, ongoing losses, and continued cash burn) and very bearish technicals (price well below key moving averages with negative momentum). Corporate events add additional dilution/reverse-split risk despite improved near-term liquidity from the recent capital raise, while valuation support is limited because the company is loss-making and has no stated dividend yield.
Positive Factors
Low leverage
Very low leverage limits interest-burden pressure and reduces financial risk compared with a heavily indebted structure. This gives Sunshine Biopharma greater flexibility to allocate resources toward drug development and commercialization while retaining capacity to manage operating volatility.
Negative Factors
Sharp revenue decline
A roughly 41% TTM revenue decline indicates a substantial loss of commercialization momentum rather than merely slower expansion. Unless product demand and sales execution improve, weaker revenue will constrain operating leverage and make sustainable profitability harder to achieve.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low leverage limits interest-burden pressure and reduces financial risk compared with a heavily indebted structure. This gives Sunshine Biopharma greater flexibility to allocate resources toward drug development and commercialization while retaining capacity to manage operating volatility.
Read all positive factors
Sunshine Biopharma (SBFM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$646.54K
Dividend YieldN/A
Average Volume (3M)10.97M
Price to Earnings (P/E)―
Beta (1Y)1.74
Revenue Growth-2.74%
EPS Growth60.85%
CountryUS
Employees50
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-10.15
Shares Outstanding4,310,301
10 Day Avg. Volume2,383,309
30 Day Avg. Volume10,972,466
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.14
P/FCF Ratio-0.93
Enterprise Value/Market Cap-15.76
Enterprise Value/Revenue-0.29
Enterprise Value/Gross Profit-0.97
Enterprise Value/Ebitda1.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.3
Revenue Forecast (FY)$35.40M
Sunshine Biopharma Business Overview & Revenue Model
Company Description
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-dif...
Sunshine Biopharma Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
64
Positive
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.35M | 36.31M | 34.87M | 24.09M | 4.35M | 228.43K |
| Gross Profit | 10.53M | 11.92M | 10.67M | 8.34M | 1.70M | 110.60K |
| EBITDA | -5.26M | -5.62M | -5.14M | -3.82M | -26.45M | -12.09M |
| Net Income | -5.83M | -5.98M | -5.13M | -4.51M | -26.74M | -12.44M |
Balance Sheet | ||||||
| Total Assets | 33.63M | 30.08M | 30.56M | 27.35M | 29.55M | 2.20M |
| Cash, Cash Equivalents and Short-Term Investments | 13.75M | 9.12M | 9.69M | 16.29M | 21.83M | 2.05M |
| Total Debt | 678.34K | 812.42K | 952.48K | 657.71K | 765.26K | 1.90M |
| Total Liabilities | 6.09M | 7.04M | 7.06M | 6.14M | 7.92M | 1.99M |
| Stockholders Equity | 27.54M | 23.04M | 23.50M | 21.21M | 21.63M | 211.66K |
Cash Flow | ||||||
| Free Cash Flow | -4.60M | -5.51M | -14.85M | -9.56M | -5.55M | -1.83M |
| Operating Cash Flow | -5.33M | -5.33M | -12.53M | -8.78M | -5.25M | -1.83M |
| Investing Cash Flow | -278.14K | -836.31K | -2.32M | -656.15K | -14.62M | 0.00 |
| Financing Cash Flow | 8.60M | 4.75M | 9.29M | 3.43M | 39.47M | 2.90M |
Sunshine Biopharma Technical Analysis
Negative
1.14
Price Trends
0.81
Negative
1.34
Negative
5.77
Negative
Market Momentum
-0.20
Negative
24.60
Positive
11.69
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBFM, the sentiment is Negative. The current price of 1.14 is above the 20-day moving average (MA) of 0.41, above the 50-day MA of 0.81, and below the 200-day MA of 5.77, indicating a bearish trend. The MACD of -0.20 indicates Negative momentum. The RSI at 24.60 is Positive, neither overbought nor oversold. The STOCH value of 11.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SBFM.
Sunshine Biopharma Risk Analysis
Sunshine Biopharma disclosed 32 risk factors in its most recent earnings report. Sunshine Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
If we are unable to continue to meet the listing requirements of Nasdaq, our common stock will be delisted Q4, 2023
Sunshine Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $4.06M | -1.18 | -34.25% | ― | 10.01% | 95.01% | |
42 Neutral | $5.32M | -0.91 | -53.56% | ― | 47.00% | 50.49% | |
41 Neutral | $646.54K | -0.01 | -24.23% | ― | -2.74% | 60.85% | |
38 Underperform | $1.45M | -0.04 | 841.81% | ― | -11.91% | -285.26% | |
32 Underperform | $23.16M | -0.16 | -156.78% | ― | ― | 94.90% |
* Healthcare Sector Average
SBFM
Sunshine Biopharma
0.15
-19.45
-99.23%
SNOA
Sonoma Pharmaceuticals
1.11
-2.89
-72.25%
YCBD
cbdMD
0.36
-0.66
-64.51%
IMCC
IM Cannabis Corp
0.88
-42.02
-97.96%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
4.86
-27.14
-84.81%
Sunshine Biopharma Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Sunshine Biopharma Approves Dilutive Share Issuance Plan
Negative
Oct 14, 2026
On October 13, 2026, Sunshine Biopharma’s CEO, Dr. Steve N. Slilaty, who controls about 90% of the company’s voting power, approved issuing more than 20% of the firm’s outstanding common shares at a discount to the Nasdaq minimum...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Sunshine Biopharma Completes $6 Million Public Offering
Positive
Oct 9, 2026
On October 8, 2026, Sunshine Biopharma entered a placement agent agreement with Aegis Capital for a reasonable best efforts public offering of 10,509,082 common units and 400,000 pre‑funded units, each combining common stock or pre‑fun...
Business Operations and StrategyRegulatory Filings and ComplianceStock Split
Sunshine Biopharma CEO Authorizes Potential Reverse Stock Split
Negative
Sep 16, 2026
On September 15, 2026, Sunshine Biopharma’s majority voting shareholder and CEO, Dr. Steve N. Slilaty, approved a written consent authorizing the board to implement a reverse split of the company’s common stock at a ratio of up to 1-fo...
Private Placements and FinancingRegulatory Filings and Compliance
Sunshine Biopharma Adjusts Series B Warrant Exercise Price
Negative
Sep 11, 2026
As of the date of the filing referenced in the report, Sunshine Biopharma Inc. disclosed that recent sales of its common stock under a previously announced at-the-market offering triggered an adjustment to the exercise price of its outstanding Ser...
Executive/Board Changes
Sunshine Biopharma Announces Upcoming Board Leadership Change
Neutral
Aug 28, 2026
On August 25, 2026, Sunshine Biopharma Inc. disclosed that director Dr. Andrew Keller notified the company he will not seek or accept reelection to its Board of Directors. His current term is set to expire at the company’s next annual shareh...
Private Placements and FinancingRegulatory Filings and Compliance
Sunshine Biopharma Adjusts Series B Warrant Terms
Neutral
Aug 3, 2026
As of the latest report filing date, Sunshine Biopharma Inc. disclosed that recent sales of its common stock under a previously announced at-the-market offering triggered an adjustment to the terms of its outstanding Series B Warrants. The exercis...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.